Active	Status	Sponsor type	Region	Phase	Filter
8 Active 0 Inactive 8 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   - « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   Show only changed items Enrollment:

Advanced Filters

8 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Stone, Melody
ADapt, NCT05369403: A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab	Completed	3	86	US	Lebrikizumab, LY3650150, DRM06	Eli Lilly and Company	Atopic Dermatitis	01/24	02/25
BRAVE-AA-PEDS, NCT05723198: A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata	Recruiting	3	595	Europe, Canada, Japan, US, RoW	Baricitinib, LY3009104, Placebo	Eli Lilly and Company	Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases, Skin Diseases, Pathological Conditions, Anatomical	09/27	08/29
ADtouch, NCT06921759: A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis	Not yet recruiting	3	206	Canada, Japan, US, RoW	Lebrikizumab, LY3650150, Placebo	Eli Lilly and Company	Atopic Hand and Foot Dermatitis	07/26	09/26
NCT06436183: A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis	Recruiting	2	60	Canada, US	Camoteskimab, APL-9109, AVTX-007, CERC-007, AEVI-007, MEDI2338, Placebo	Apollo Therapeutics Ltd	Atopic Dermatitis, Atopic, Dermatitis, Dermatologic Disease, Eczema, Eczema Atopic Dermatitis, Eczema, Atopic	02/25	06/25
RECAST DLE, NCT05591222 / 2022-000831-21: Study of Daxdilimab (HZN-7734) in Participants With Moderate-to-Severe Primary Discoid Lupus Erythematosus	Active, not recruiting	2	72	Europe, Canada, US, RoW	Placebo, Daxdilimab, HZN-7734	Amgen, Horizon Therapeutics Ireland DAC	Discoid Lupus Erythematosus	08/25	08/25
Murphy, Clarissa
EMBARQ-CSU1, NCT06445023: A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria	Recruiting	3	915	Europe, Canada, US, RoW	barzolvolimab, Matching placebo	Celldex Therapeutics	Chronic Spontaneous Urticaria	10/26	04/27
NCT06436183: A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis	Recruiting	2	60	Canada, US	Camoteskimab, APL-9109, AVTX-007, CERC-007, AEVI-007, MEDI2338, Placebo	Apollo Therapeutics Ltd	Atopic Dermatitis, Atopic, Dermatitis, Dermatologic Disease, Eczema, Eczema Atopic Dermatitis, Eczema, Atopic	02/25	06/25
RECAST DLE, NCT05591222 / 2022-000831-21: Study of Daxdilimab (HZN-7734) in Participants With Moderate-to-Severe Primary Discoid Lupus Erythematosus	Active, not recruiting	2	72	Europe, Canada, US, RoW	Placebo, Daxdilimab, HZN-7734	Amgen, Horizon Therapeutics Ireland DAC	Discoid Lupus Erythematosus	08/25	08/25

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Stone, Melody
ADapt, NCT05369403: A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab	Completed	3	86	US	Lebrikizumab, LY3650150, DRM06	Eli Lilly and Company	Atopic Dermatitis	01/24	02/25
BRAVE-AA-PEDS, NCT05723198: A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata	Recruiting	3	595	Europe, Canada, Japan, US, RoW	Baricitinib, LY3009104, Placebo	Eli Lilly and Company	Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases, Skin Diseases, Pathological Conditions, Anatomical	09/27	08/29
ADtouch, NCT06921759: A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis	Not yet recruiting	3	206	Canada, Japan, US, RoW	Lebrikizumab, LY3650150, Placebo	Eli Lilly and Company	Atopic Hand and Foot Dermatitis	07/26	09/26
NCT06436183: A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis	Recruiting	2	60	Canada, US	Camoteskimab, APL-9109, AVTX-007, CERC-007, AEVI-007, MEDI2338, Placebo	Apollo Therapeutics Ltd	Atopic Dermatitis, Atopic, Dermatitis, Dermatologic Disease, Eczema, Eczema Atopic Dermatitis, Eczema, Atopic	02/25	06/25
RECAST DLE, NCT05591222 / 2022-000831-21: Study of Daxdilimab (HZN-7734) in Participants With Moderate-to-Severe Primary Discoid Lupus Erythematosus	Active, not recruiting	2	72	Europe, Canada, US, RoW	Placebo, Daxdilimab, HZN-7734	Amgen, Horizon Therapeutics Ireland DAC	Discoid Lupus Erythematosus	08/25	08/25
Murphy, Clarissa
EMBARQ-CSU1, NCT06445023: A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria	Recruiting	3	915	Europe, Canada, US, RoW	barzolvolimab, Matching placebo	Celldex Therapeutics	Chronic Spontaneous Urticaria	10/26	04/27
NCT06436183: A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis	Recruiting	2	60	Canada, US	Camoteskimab, APL-9109, AVTX-007, CERC-007, AEVI-007, MEDI2338, Placebo	Apollo Therapeutics Ltd	Atopic Dermatitis, Atopic, Dermatitis, Dermatologic Disease, Eczema, Eczema Atopic Dermatitis, Eczema, Atopic	02/25	06/25
RECAST DLE, NCT05591222 / 2022-000831-21: Study of Daxdilimab (HZN-7734) in Participants With Moderate-to-Severe Primary Discoid Lupus Erythematosus	Active, not recruiting	2	72	Europe, Canada, US, RoW	Placebo, Daxdilimab, HZN-7734	Amgen, Horizon Therapeutics Ireland DAC	Discoid Lupus Erythematosus	08/25	08/25